Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

3.25  +0.03 (+0.93%)

After market: 3.25 0 (0%)

Fundamental Rating

4

Overall RLAY gets a fundamental rating of 4 out of 10. We evaluated RLAY against 550 industry peers in the Biotechnology industry. While RLAY has a great health rating, there are worries on its profitability. RLAY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RLAY had negative earnings in the past year.
In the past year RLAY has reported a negative cash flow from operations.
RLAY had negative earnings in each of the past 5 years.
In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -41.71%, RLAY perfoms like the industry average, outperforming 55.45% of the companies in the same industry.
The Return On Equity of RLAY (-46.23%) is better than 67.27% of its industry peers.
Industry RankSector Rank
ROA -41.71%
ROE -46.23%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RLAY has been increased compared to 1 year ago.
The number of shares outstanding for RLAY has been increased compared to 5 years ago.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.64, we must say that RLAY is in the distress zone and has some risk of bankruptcy.
RLAY's Altman-Z score of 0.64 is fine compared to the rest of the industry. RLAY outperforms 64.55% of its industry peers.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.64
ROIC/WACCN/A
WACC9.77%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 19.96 indicates that RLAY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 19.96, RLAY belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
A Quick Ratio of 19.96 indicates that RLAY has no problem at all paying its short term obligations.
The Quick ratio of RLAY (19.96) is better than 94.00% of its industry peers.
Industry RankSector Rank
Current Ratio 19.96
Quick Ratio 19.96
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.62% over the past year.
The Revenue for RLAY has decreased by -60.83% in the past year. This is quite bad
Measured over the past years, RLAY shows a very strong growth in Revenue. The Revenue has been growing by 48.92% on average per year.
EPS 1Y (TTM)22.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.58%
Revenue 1Y (TTM)-60.83%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RLAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.25% on average per year.
The Revenue is expected to grow by 54.93% on average over the next years. This is a very strong growth
EPS Next Y20.29%
EPS Next 2Y10.52%
EPS Next 3Y6.32%
EPS Next 5Y10.25%
Revenue Next Year-25.76%
Revenue Next 2Y-13.94%
Revenue Next 3Y12.21%
Revenue Next 5Y54.93%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.52%
EPS Next 3Y6.32%

More info and screens

0

5. Dividend

5.1 Amount

RLAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (8/11/2025, 8:01:58 PM)

After market: 3.25 0 (0%)

3.25

+0.03 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners86.99%
Inst Owner Change0.17%
Ins Owners1.43%
Ins Owner Change-1.06%
Market Cap557.18M
Analysts84.44
Price Target14.79 (355.08%)
Short Float %15.41%
Short Ratio11.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.52%
Min EPS beat(2)7.59%
Max EPS beat(2)21.46%
EPS beat(4)4
Avg EPS beat(4)14.07%
Min EPS beat(4)7.59%
Max EPS beat(4)21.46%
EPS beat(8)8
Avg EPS beat(8)14.85%
EPS beat(12)9
Avg EPS beat(12)9.47%
EPS beat(16)10
Avg EPS beat(16)-14.69%
Revenue beat(2)1
Avg Revenue beat(2)37542.2%
Min Revenue beat(2)-100%
Max Revenue beat(2)75184.3%
Revenue beat(4)1
Avg Revenue beat(4)18721.1%
Min Revenue beat(4)-100%
Max Revenue beat(4)75184.3%
Revenue beat(8)3
Avg Revenue beat(8)11727.8%
Revenue beat(12)4
Avg Revenue beat(12)7798.91%
Revenue beat(16)6
Avg Revenue beat(16)5879.62%
PT rev (1m)0%
PT rev (3m)-14.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.58%
EPS NY rev (1m)0%
EPS NY rev (3m)10.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-98.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)36.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 72.56
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.04
BVpS4.21
TBVpS4.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.71%
ROE -46.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.79%
Cap/Sales 8.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.96
Quick Ratio 19.96
Altman-Z 0.64
F-Score3
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.58%
EPS Next Y20.29%
EPS Next 2Y10.52%
EPS Next 3Y6.32%
EPS Next 5Y10.25%
Revenue 1Y (TTM)-60.83%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-25.76%
Revenue Next 2Y-13.94%
Revenue Next 3Y12.21%
Revenue Next 5Y54.93%
EBIT growth 1Y42.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.97%
EBIT Next 3Y3.61%
EBIT Next 5Y13.4%
FCF growth 1Y-6.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.92%
OCF growth 3YN/A
OCF growth 5YN/A